Latest Breaking News On - Resistance programme - Page 1 : comparemela.com

Search jobs Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board Destiny Pharma Plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces the appointment of Professor Mark Wilcox to its Scientific Advisory Board (SAB). Professor Wilcox is a consultant microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospitals and is Lead on Clostridium difficile infection for Public Health England (PHE). He also has advisory roles to UK SAGE (COVID-19), NHS England’s Infection Prevention & Control national team and PHE’s Rapid Review Panel (reviewing the utility of infection prevention and control products for the NHS), and is a member of the UK NHS Antimicrobial Resistance Programme Board.

United kingdomMark wilcoxHealthcare associated infection research groupAntimicrobial resistance programme boardPublic health englandUniversity of leedsRapid review panelDestiny pharma plcProfessor mark wilcoxScientific advisory boardLeeds teaching hospitalsInfection preventionReview panelResistance programmeBill loveChief scientific officer